Recent Groundbreaking Research in Space Travel

September 14, 2022
5min read
image of person walking in space

With the growing interest in space flight and deep space exploration, more research is focusing on how to make life outside of earth habitable for human beings, and at what cost. In this blog, we’ll look at the market landscape of space travel, recent innovation activity, and scientific literature to gain a full picture of where our understanding of life beyond earth is headed.

Market Overview:

According to the Cypris Innovation Dashboard, over the past year alone, 15 new organizations entered the space travel industry (13 of which were startups) and the majority were based in USA. The past year also saw 406 new patents across 22 different countries, 10,549 new research papers, and 26,156 news articles published in the space.  The majority of news articles focused on new products, and across the board media coverage was positive.

space travel cypris innovation dashboard
News category breakdown

Of the patents published, 15.46% were created by the top 3 entities: NANJING SANLE GROUP CO LTD, ANHUI HUADONG PHOTOELEC TECH, and EMULATE INC. Below, you can see the breakdown of patent activity by region.

space travel cypris patent activity
Patent count by region

In the recent months, a number of new scientific studies have been released on efforts to make life in outer space habitable for human beings, and the impact of travel on the body and brain. Let's dive into a few of these findings.

Creating Oxygen in Space Using Magnets:

spaceship launching with smoke in background

Researchers at the University of Warwick have invented a new way to make oxygen for astronauts using magnets. To provide oxygen in space, NASA currently uses centrifuges, which are large machines that require significant mass, power, and maintenance. As a result, scientists have been looking for a sustainable way to create air in space.

This study focused on the phenomenon of magnetically-induced buoyancy. The researchers engineered a procedure to detach gas bubbles from electrode surfaces in microgravity environments at the Bremen Drop Tower. The results revealed for the first time that gas bubbles can be ‘attracted to’ and ‘repelled from’ a neodymium magnet in microgravity within various solutions.

According to Dr. Katharina Brinkert of the University of Warwick Department of Chemistry Center for Applied Space Technology and Microgravity (ZARM), “Efficient phase separation in reduced gravitational environments is an obstacle for human space exploration and known since the first flights to space in the 1960s. This phenomenon is a particular challenge for the life support system onboard spacecraft and the International Space Station (ISS) as oxygen for the crew is produced in water electrolyzer systems and requires separation from the electrode and liquid electrolyte.”

The results of this study could help generate breathable atmospheres for future space travel to the moon and Mars.

Space Travel’s Impact on the Body's Bone Mass & Stem Cells:

image of spaceman in space

For those who stay in space for longer periods of time, the most prominent side effect is the loss of bone mass. New research now claims that living in space can also accelerate the process of bone aging, and irreparably damage bone structure.

The study assessed 14 male and three female astronauts, average age 47, whose missions ranged from four to seven months in space, with an average of about 5-1/2 months. The results showed that 1 year after their return from space, the astronauts on average exhibited 2.1% reduced bone mineral density at the tibia and 1.3% reduced bone strength. Nine of the 17 astronauts had not completely recovered a full year after returning from space.

"Astronauts experienced significant bone loss during six-month spaceflights - loss that we would expect to see in older adults over two decades on Earth, and they only recovered about half of that loss after one year back on Earth," Gabel said.

Additionally, another recent study focused on 14 astronauts from NASA’s space shuttle program whose white blood samples were stored for 20 years. Researchers found that the astronauts were more likely to have somatic mutations in their genes. The DNA mutations in blood-forming stem cells are at the root of several types of blood cancer.

Space Travel’s Impact on the Brain:

We know that space travel impacts the body, but what does it do to the brain? In this study, 12 cosmonauts who spent an average of six months aboard the International Space Station were scanned in an MRI scanner pre-flight, ten days after flight, and at a follow-up time point seven months after flight.

The results revealed "significant microstructural changes" in the white matter that manages communications within the brain, and to and from the rest of the body, as well as fluid shifts. In particular, the research team spotted changes in neural tracts related to sensory and motor functions, and believe this could have something to do with the cosmonauts' adaptation to life in microgravity while in outer space.

Whether through creating oxygen in outer space, or studying how travel impacts the brain and body, significant advances are being made in the space travel industry. For more data on patents and innovative research papers in the space travel field, visit cypris.ai and get started with access to the innovation dashboard.

If you’d like to explore recent patents filed, you can search through our global patent search engine for free here: https://cypris.ai/patents/allrecords

Sources:

Cypris innovation dashboard cypris.ai ; Query: space travel

https://www.precedenceresearch.com/space-tourism-market

https://interestingengineering.com/science/first-researchers-invent-oxygen-magnets-space-exploration

https://www.nature.com/articles/s41526-022-00212-9

https://www.sciencedaily.com/releases/2022/07/220729173222.htm

https://www.nature.com/articles/s41598-022-13461-1

https://www.slashgear.com/946243/scientists-discover-space-travel-accelerates-aging/

https://www.frontiersin.org/articles/10.3389/fncir.2022.815838/full

Similar insights you might enjoy

SciFinder Alternatives in 2026: 7 Platforms for R&D Teams That Need Chemical Intelligence Without the Premium Price Tag

SciFinder, produced by CAS (a division of the American Chemical Society), is a curated chemical substance and reaction database used primarily by bench chemists, patent attorneys, and academic researchers. Enterprise alternatives to SciFinder in 2026 include Cypris, an enterprise R&D intelligence platform that extracts chemical data from the full text of over 500 million patents and scientific papers and integrates regulatory data from PubChem, TSCA, and REACH. Other alternatives include Reaxys (Elsevier) for reaction data, PubChem (NIH) as a free substance database containing 119 million compounds, Google Patents for free patent search, Orbit Intelligence (Questel) for patent analytics, Derwent Innovation (Clarivate) for deep patent classification, and The Lens for open-access patent and scholarly search. Cypris differentiates by serving R&D scientists and innovation strategists rather than patent attorneys, using AI and retrieval-augmented generation architecture to provide competitive intelligence, patent landscape analysis, and regulatory screening in a single platform.

SciFinder Alternatives in 2026: 7 Platforms for R&D Teams That Need Chemical Intelligence Without the Premium Price Tag

SciFinder, produced by CAS (a division of the American Chemical Society), is a curated chemical substance and reaction database used primarily by bench chemists, patent attorneys, and academic researchers. Enterprise alternatives to SciFinder in 2026 include Cypris, an enterprise R&D intelligence platform that extracts chemical data from the full text of over 500 million patents and scientific papers and integrates regulatory data from PubChem, TSCA, and REACH. Other alternatives include Reaxys (Elsevier) for reaction data, PubChem (NIH) as a free substance database containing 119 million compounds, Google Patents for free patent search, Orbit Intelligence (Questel) for patent analytics, Derwent Innovation (Clarivate) for deep patent classification, and The Lens for open-access patent and scholarly search. Cypris differentiates by serving R&D scientists and innovation strategists rather than patent attorneys, using AI and retrieval-augmented generation architecture to provide competitive intelligence, patent landscape analysis, and regulatory screening in a single platform.

The Best Chemical Intelligence Platforms for R&D Teams in 2026

The leading chemical intelligence platforms for R&D teams in 2026 include Cypris, Reaxys, Orbit Intelligence, Derwent Innovation, Google Patents, The Lens, and PubChem. Late-stage failures in chemical development programs are frequently caused by incomplete early-stage intelligence rather than flawed science, with common triggers including undiscovered blocking patents, unexpected regulatory changes under frameworks like TSCA and REACH, and competitive developments invisible to narrow scanning tools. The choice of intelligence platform directly affects whether development programs survive to commercialization, because fragmented point tools that cover only patents, or only literature, or only substance data create systematic blind spots that compound across R&D portfolios. Cypris (cypris.ai) is the most comprehensive enterprise option, offering unified access to over 500 million patents and scientific papers through a proprietary R&D ontology, with competitive landscape mapping, patent portfolio analytics, freedom-to-operate assessment, material synthesis trend tracking, and AI-generated intelligence reports through Cypris Q that serve as direct inputs to stage-gate reviews.

The Best Chemical Intelligence Platforms for R&D Teams in 2026

The leading chemical intelligence platforms for R&D teams in 2026 include Cypris, Reaxys, Orbit Intelligence, Derwent Innovation, Google Patents, The Lens, and PubChem. Late-stage failures in chemical development programs are frequently caused by incomplete early-stage intelligence rather than flawed science, with common triggers including undiscovered blocking patents, unexpected regulatory changes under frameworks like TSCA and REACH, and competitive developments invisible to narrow scanning tools. The choice of intelligence platform directly affects whether development programs survive to commercialization, because fragmented point tools that cover only patents, or only literature, or only substance data create systematic blind spots that compound across R&D portfolios. Cypris (cypris.ai) is the most comprehensive enterprise option, offering unified access to over 500 million patents and scientific papers through a proprietary R&D ontology, with competitive landscape mapping, patent portfolio analytics, freedom-to-operate assessment, material synthesis trend tracking, and AI-generated intelligence reports through Cypris Q that serve as direct inputs to stage-gate reviews.

Cypris vs. Perplexity for R&D Research: An Honest Comparison for Enterprise Teams in 2026

Cypris and Perplexity are different categories of research tool optimized for different use cases. Perplexity is a general-purpose AI search engine that synthesizes information from the open web, excelling at breadth, speed, commercial context, and accessibility across all domains. Cypris is an enterprise R&D intelligence platform that searches over 500 million patents, scientific papers, and technical documents through a proprietary R&D ontology, excelling at patent intelligence, source verifiability, technical depth, and structured R&D deliverables. In a January 2026 head-to-head evaluation using a 100-point R&D rubric, Cypris scored 89 out of 100 and Perplexity scored 65 out of 100, with Cypris outperforming on source authority, technical depth, competitive and IP intelligence, and R&D actionability, while Perplexity outperformed on commercial timeline specificity and geographic comprehensiveness. Cypris holds official API partnerships with OpenAI, Anthropic, and Google and meets Fortune 500 enterprise security requirements. Perplexity does not provide direct access to patent databases or structured IP intelligence. Both tools serve legitimate research needs, with Perplexity better suited for exploratory and general business research and Cypris better suited for patent-grounded, security-compliant enterprise R&D intelligence.

Cypris vs. Perplexity for R&D Research: An Honest Comparison for Enterprise Teams in 2026

Cypris and Perplexity are different categories of research tool optimized for different use cases. Perplexity is a general-purpose AI search engine that synthesizes information from the open web, excelling at breadth, speed, commercial context, and accessibility across all domains. Cypris is an enterprise R&D intelligence platform that searches over 500 million patents, scientific papers, and technical documents through a proprietary R&D ontology, excelling at patent intelligence, source verifiability, technical depth, and structured R&D deliverables. In a January 2026 head-to-head evaluation using a 100-point R&D rubric, Cypris scored 89 out of 100 and Perplexity scored 65 out of 100, with Cypris outperforming on source authority, technical depth, competitive and IP intelligence, and R&D actionability, while Perplexity outperformed on commercial timeline specificity and geographic comprehensiveness. Cypris holds official API partnerships with OpenAI, Anthropic, and Google and meets Fortune 500 enterprise security requirements. Perplexity does not provide direct access to patent databases or structured IP intelligence. Both tools serve legitimate research needs, with Perplexity better suited for exploratory and general business research and Cypris better suited for patent-grounded, security-compliant enterprise R&D intelligence.